Arumugam Nagalingam - Concepedia

Concepedia

Author

Arumugam Nagalingam

Sidney Kimmel Comprehensive Cancer Center ORCID

Also Known As

A Nagalingam, A. Nagalingam, Aroun kumar Nagalingam, Arumugam Nagalingam, Nagalingam, Arumugam

99

Publications

2.1K

Citations

23

H-Index

34

Concepts

All Affiliations

Sidney Kimmel Comprehensive Cancer Center Johns Hopkins University University of Maryland, Baltimore Emory University Winship Cancer Institute

AN

About

Arumugam Nagalingam is an author at Sidney Kimmel Comprehensive Cancer Center specializing in medicine, tumor biology, and cell biology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	7	7	793
2	Cell Biology	6	6	763
3	Biochemistry	2	2	223
4	Health Sciences	1	1	30
5	Natural Sciences	1	1	52

Arumugam Nagalingam

×

27

Publications

2.1K

Citations

23

H-Index

	Year	Citations
A Procarcinogenic Colon Microbe Promotes Breast Tumorigenesis and Metastatic Progression and Concomitantly Activates Notch and β-Catenin Axes Sheetal Parida, Shaoguang Wu, Sumit Siddharth, Cancer Discovery	2021	226
ADIPOQ/adiponectin induces cytotoxic autophagy in breast cancer cells through STK11/LKB1-mediated activation of the AMPK-ULK1 axis Seung Joon Chung, Ganji Purnachandra Nagaraju, Arumugam Nagalingam, Autophagy Breast Cancer GrowthMitophagyBreast OncologyImmunologyCell Death	2017	220
Adiponectin Antagonizes the Oncogenic Actions of Leptin in Hepatocellular Carcinogenesis Dipali Sharma, Jason Wang, Ping Fu, Hepatology	2010	177
LKB1 is required for adiponectin-mediated modulation of AMPK–S6K axis and inhibition of migration and invasion of breast cancer cells Arumugam Nagalingam, Diansheng Zhong, Weibo Zhou, Oncogene Signal TransductionMolecular PhysiologyBiochemistryAdiponectin-mediated ModulationMedicine	2009	171
Adiponectin Modulates C-Jun N-Terminal Kinase and Mammalian Target of Rapamycin and Inhibits Hepatocellular Carcinoma Neeraj K. Saxena, Ping Fu, Arumugam Nagalingam, Gastroenterology Mammalian TargetHepatologyMedicineLiver PhysiologyPathology	2010	156
Honokiol activates AMP-activated protein kinase in breast cancer cells via an LKB1-dependent pathway and inhibits breast carcinogenesis Arumugam Nagalingam, Jack L. Arbiser, Michael Y. Bonner, Breast Cancer Research	2012	99
Honokiol inhibits epithelial—mesenchymal transition in breast cancer cells by targeting signal transducer and activator of transcription 3/Zeb1/E‐cadherin axis Dimiter Avtanski, Arumugam Nagalingam, Michael Y. Bonner, Molecular Oncology	2014	97
Mechanistic Elucidation of the Antitumor Properties of Withaferin A in Breast Cancer Arumugam Nagalingam, Panjamurthy Kuppusamy, Shivendra V. Singh, Cancer Research	2014	95
Activation of tumor suppressor LKB1 by honokiol abrogates cancer stem-like phenotype in breast cancer via inhibition of oncogenic Stat3 Sonali Sengupta, Arumugam Nagalingam, Nethaji Muniraj, Oncogene Tumor Suppressor Lkb1Oncogenic Stat3Signaling PathwayMedicineReceptor Tyrosine Kinase	2017	93
Survivin upregulation, dependent on leptin–EGFR–Notch1 axis, is essential for leptin-induced migration of breast carcinoma cells Brandi B. Knight, Gabriela Oprea‐Ilies, Arumugam Nagalingam, Endocrine Related Cancer	2011	80

Page 1